Loading
Extracellular Vesicles in Disease / Cancer Cells and Metastasis / Nanoplatforms for Cancer Theranostics · Journal article
Journal of Nanobiotechnology · September 7, 2026
Early or partial results. Treat as a signal, not a conclusion.
This is a preclinical development report describing engineered fusion cellular vesicles (Fus-CVs) combined with a sprayable alginate hydrogel for local delivery to surgical sites in mice. The work demonstrates proof-of-concept in vitro and in a mouse postoperative recurrence model, but contains no human data, quantified efficacy endpoints, or comparative controls, and is therefore in early development stage.
Preclinical in vitro and mouse tumor model study. Mouse postoperative recurrence model; in vitro cell culture systems. Specific tumor type and mouse strain not stated.. Intervention: Sprayable hydrogel loaded with fusion cellular vesicles (Fus-CVs) co-expressing PD-1 and CD36, formed by crosslinking sodium alginate with calcium chloride and manganese chloride..
Fus-CVs co-express PD-1 and CD36 to engage tumor PD-L1 and oxidized lipids, reversing T cell exhaustion. Sprayable hydrogel formed by crosslinking sodium alginate with calcium chloride and manganese chloride enables sustained local delivery. In vitro experiments and primary tumor model confirmed dual targeting of PD-L1 and oxidized lipids with restoration of T cell effector function.
No systemic toxicity data presented despite claim of reduced systemic toxicity.
This is a preclinical report and does not yet support clinical decision-making. Translation to human use would require pharmacokinetics, toxicology, manufacturing scale-up, and clinical trial design before human testing.
Preclinical proof-of-concept in engineered cellular vesicles and mouse tumor models; no human data, no efficacy endpoint with confidence intervals or statistical comparison, and no toxicity data reported.
As stated by the source record.
This is a preclinical report and does not yet support clinical decision-making. Translation to human use would require pharmacokinetics, toxicology, manufacturing scale-up, and clinical trial design before human testing.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.
Surgical resection often leaves residual lesions that lead to tumor recurrence and high mortality across various cancer types, a challenge that is particularly pronounced in oral squamous cell carcinoma. Herein, we developed a sprayable hydrogel loaded with fusion cellular vesicles (Fus-CVs) and characterized its structural and mechanical properties for the prevention of postoperative tumor recurrence. Fus-CVs co‑express PD‑1 to engage PD‑L1 on tumor cells and CD36 to competitively bind oxidized lipids in the tumor microenvironment, thereby effectively reversing T cell exhaustion and restoring T cell effector function. Additionally, the sprayable hydrogel, formed by crosslinking sodium alginate (SA) with the ionic solution (calcium chloride, CaCl 2; manganese chloride, MnCl 2 ), enables sustained local delivery of Fus‑CVs to potentiate T cell‑mediated killing of residual tumor cells. In vitro experiments and primary tumor model confirmed that Fus‑CVs specifically achieve dual targeting of PD-L1 on tumor cells and oxidized lipids in the tumor microenvironment, reverse T cell exhaustion and achieve combination therapy. In an established postoperative recurrence mouse model, the SA solution containing Fus-CVs and the ionic solution could be co-sprayed to rapidly form a conformal, uniform and stable layer on irregular tissue surfaces, enabling sustained local release of Fus-CVs and achieve effective tumor recurrence suppression. Fus‑CVs-loaded sprayable hydrogel not only achieves dual functionality in immune checkpoint blockade and lipid metabolic regulation but also offers localized controlled release, and reduced systemic toxicity, thereby presenting a clinically translatable strategy for postoperative recurrence prevention.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.